Literature DB >> 11062045

Molecular characterization of guinea pig-adapted variants of Ebola virus.

V E Volchkov1, A A Chepurnov, V A Volchkova, V A Ternovoj, H D Klenk.   

Abstract

Serial passage of initially nonlethal Ebola virus (EBOV) in outbred guinea pigs resulted in the selection of variants with high pathogenicity. Nucleotide sequence analysis of the complete genome of the guinea pig-adapted variant 8mc revealed that it differed from wild-type virus by eight mutations. No mutations were identified in nontranscribed regions, including leader, trailer, and intragenic sequences. Among noncoding regions the only base change was found in the VP30 gene. Two silent base changes were found in the open reading frame (ORF) encoding NP protein. Nucleotide changes resulting in single-amino-acid exchanges were identified in both NP and L genes. Three other mutations found in VP24 caused amino acid substitutions, which are responsible for larger structural changes of this protein, as indicated by an alteration in electrophoretic mobility. A highly pathogenic EBOV variant K5 from another passaging series showed an amino acid substitution at nearly the same location in the VP24 gene, suggesting the importance of this protein in the adaptation process. In addition, sequence variability of the GP gene was found when plaque-purified clones of EBOV-8mc were analyzed. Three of five viral clones showed insertion of one uridine residue at the GP gene-editing site, which led to a significant change in the expression of virus glycoproteins. This observation suggests that the editing site is a hot spot for insertion and deletion of nucleotides, not only at the level of transcription but also of genome replication. Irrespective of the number of uridine residues at the editing site, all plaque-purified clones of EBOV variant 8mc resembled each other in their pathogenicity for guinea pigs, indicating either the absence or only supportive role of mutations in the GP gene on the adaptation process. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11062045     DOI: 10.1006/viro.2000.0572

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  70 in total

1.  Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.

Authors:  J Brian Kimble; Delphine C Malherbe; Michelle Meyer; Bronwyn M Gunn; Marcus M Karim; Philipp A Ilinykh; Mathieu Iampietro; Khaled S Mohamed; Surendra Negi; Pavlo Gilchuk; Kai Huang; Yuri I Wolf; Werner Braun; James E Crowe; Galit Alter; Alexander Bukreyev
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

2.  Ebola virus transmission in guinea pigs.

Authors:  Gary Wong; Xiangguo Qiu; Jason S Richardson; Todd Cutts; Brad Collignon; Jason Gren; Jenna Aviles; Carissa Embury-Hyatt; Gary P Kobinger
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

3.  Evaluation of perceived threat differences posed by filovirus variants.

Authors:  Jens H Kuhn; Lori E Dodd; Victoria Wahl-Jensen; Sheli R Radoshitzky; Sina Bavari; Peter B Jahrling
Journal:  Biosecur Bioterror       Date:  2011-11-09

4.  Assessment of rodents as animal models for Reston ebolavirus.

Authors:  Emmie de Wit; Vincent J Munster; Samia A Metwally; Heinz Feldmann
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

5.  Unconventional secretion of Ebola virus matrix protein VP40.

Authors:  Olivier Reynard; St Patrick Reid; Audrey Page; Mathieu Mateo; Nathalie Alazard-Dany; Hervé Raoul; Christopher F Basler; Viktor E Volchkov
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

6.  VP24 of Marburg virus influences formation of infectious particles.

Authors:  Sandra Bamberg; Larissa Kolesnikova; Peggy Möller; Hans-Dieter Klenk; Stephan Becker
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

7.  Key genomic changes necessary for an in vivo lethal mouse marburgvirus variant selection process.

Authors:  Loreen L Lofts; Jay B Wells; Sina Bavari; Kelly L Warfield
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

8.  Filovirus replication and transcription.

Authors:  Elke Mühlberger
Journal:  Future Virol       Date:  2007-03       Impact factor: 1.831

9.  Predictive and comparative analysis of Ebolavirus proteins.

Authors:  Qian Cong; Jimin Pei; Nick V Grishin
Journal:  Cell Cycle       Date:  2015-07-09       Impact factor: 4.534

10.  Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1.

Authors:  St Patrick Reid; Charalampos Valmas; Osvaldo Martinez; Freddy Mauricio Sanchez; Christopher F Basler
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.